Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy.

Clinical epigenetics - 31 Dec 2025

Gjorgjievska Marija, Bukovec Djansel, Mehandziska Sanja, Risteski Milan, Kungulovski Ivan, Mitrev Zan, Kungulovski Goran

Abstract excerpt

In recent years, it has been demonstrated that many of the pervasive genetic defects throughout cancerogenesis occur in genes encoding chromatin regulators (CRs). We analyzed the distribution and characteristics of well-studied CRs across tens of thousands of tumor samples. Our analysis revealed that tumors with mutations in CRs are associated with high tumor mutational burden (TMB). The co-occurrence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41476223
DOI: 10.1186/s13148-025-02038-0
PMCID: PMC12866042

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy.PMID 41476223Read ↗

Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapySemantic proximity Read ↗

Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapySemantic proximity Read ↗

Genetic aberrations in chromatin factors are pervasive, mutually exclusive, associated with a high mutational burden and improved response to checkpoint immunotherapy in cancerSemantic proximity Read ↗

Genetic aberrations in chromatin factors are pervasive, mutually exclusive, associated with a high mutational burden and improved response to checkpoint immunotherapy in cancerSemantic proximity Read ↗

Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer.Semantic proximity Read ↗

eTRex Reveals Oncogenic Transcriptional Regulatory Programs Across Human CancersSemantic proximity Read ↗

Candidate cancer driver mutations in superenhancers and long-range chromatin interaction networksSemantic proximity Read ↗

Pan-cancer analysis of m5C regulator genes reveals consistent epigenetic landscape changes in multiple cancers.Semantic proximity Read ↗

Chromatin signatures of cancer.Semantic proximity Read ↗

Pan-cancer analysis of m5C regulator genes reveals consistent epigenetic landscape changes in multiple cancersSemantic proximity Read ↗

Recurrent somatic mutations in regulatory regions of human cancer genomes.Semantic proximity Read ↗

Therapy-associated mutagenesis at CTCF binding sites is shaped by chromatin context and DNA repair capacitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.